Gastrointestinal lymphomas in patients with AIDS

Area of Science:

• Oncology
• Infectious Diseases
• Gastroenterology

Background:

• Non-Hodgkin Lymphoma (NHL), particularly high-grade B-cell lymphoma, affects 5-10% of individuals with HIV infection.
• The gastrointestinal tract (GIT) is the most common extranodal site for NHL in HIV-infected patients.
• Optimal therapy for HIV-related lymphoma is debated, with gastrointestinal involvement being frequent.

Purpose of the Study:

• To investigate diagnostic procedures, therapy, and outcomes for HIV-infected patients with gastrointestinal symptoms.
• To assess the incidence of gastrointestinal NHL in HIV-positive patients presenting with GI symptoms.
• To evaluate the utility of endoscopic ultrasound (EUS) in staging and the effectiveness of CHOP chemotherapy.

Main Methods:

• Retrospective analysis of 306 HIV-infected patients identifying gastrointestinal lymphoma.
• Prospective survey involving endoscopy in 93 HIV-infected patients with gastrointestinal symptoms.
• Use of endoscopic ultrasound (EUS) for staging in selected patients before and after chemotherapy.

Main Results:

• Gastrointestinal lymphoma was found in 3.3% of patients in the retrospective analysis (median CD4 92/µL, survival 15 months).
• In the prospective study, NHL of the GIT was detected in 7.5% of 93 endoscopically examined patients (mean CD4 193/µL, survival 10 months).
• CHOP chemotherapy demonstrated high remission rates with low treatment-induced myelosuppression.

Conclusions:

• Gastrointestinal lymphoma should be considered in HIV-infected patients with unexplained gastrointestinal symptoms.
• Endoscopic ultrasound (EUS) enhances staging accuracy for gastrointestinal lymphoma.
• CHOP chemotherapy is an effective treatment for HIV-related gastrointestinal NHL, yielding good remission rates.